NASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis $33.60 -0.31 (-0.90%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunocore Stock (NASDAQ:IMCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunocore alerts:Sign Up Key Stats Today's Range$33.03▼$34.6150-Day Range$31.12▼$38.6552-Week Range$23.15▼$40.52Volume173,810 shsAverage Volume337,142 shsMarket Capitalization$1.69 billionP/E RatioN/ADividend YieldN/APrice Target$58.89Consensus RatingModerate Buy Company Overview Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Read More Immunocore Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreIMCR MarketRank™: Immunocore scored higher than 30% of companies evaluated by MarketBeat, and ranked 797th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageImmunocore has only been the subject of 3 research reports in the past 90 days.Read more about Immunocore's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -77.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -77.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 4.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.46% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 1.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.46% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 1.56%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment1.40 News SentimentImmunocore has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Immunocore this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address IMCR Stock News HeadlinesImmunocore Holdings plc (IMCR) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comImmunocore Holdings ADR Earns IBD Rating UpgradeJuly 10, 2025 | msn.comA $674B Industry Missed the Bigger PictureTV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.July 30 at 2:00 AM | Mode Mobile (Ad)Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS RegionsJune 30, 2025 | finance.yahoo.comEr-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS RegionsJune 30, 2025 | globenewswire.comIMCR - Immunocore Holdings PLC ADR Ownership | MorningstarJune 28, 2025 | morningstar.comMIMCR Immunocore Holdings plc - Seeking AlphaJune 26, 2025 | seekingalpha.comNotable Two Hundred Day Moving Average Cross - IMCRJune 24, 2025 | nasdaq.comSee More Headlines IMCR Stock Analysis - Frequently Asked Questions How have IMCR shares performed this year? Immunocore's stock was trading at $29.50 on January 1st, 2025. Since then, IMCR shares have increased by 13.9% and is now trading at $33.6050. How were Immunocore's earnings last quarter? Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) announced its quarterly earnings results on Wednesday, May, 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. The firm's revenue for the quarter was up 33.6% compared to the same quarter last year. When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO. Who are Immunocore's major shareholders? Top institutional investors of Immunocore include TD Asset Management Inc (0.57%). Insiders that own company stock include Bros Advisors Lp Baker and Leger Tina Amber St. View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunocore own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/07/2025Today7/30/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMCR CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees320Year FoundedN/APrice Target and Rating Average Price Target for Immunocore$58.89 High Price Target$100.00 Low Price Target$24.00 Potential Upside/Downside+75.2%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.09 million Net Margins-6.48% Pretax Margin-6.83% Return on Equity-5.86% Return on Assets-2.09% Debt Debt-to-Equity Ratio1.03 Current Ratio6.36 Quick Ratio6.31 Sales & Book Value Annual Sales$310.20 million Price / Sales5.44 Cash FlowN/A Price / Cash FlowN/A Book Value$7.20 per share Price / Book4.67Miscellaneous Outstanding Shares50,230,000Free Float45,010,000Market Cap$1.69 billion OptionableOptionable Beta0.77 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:IMCR) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.